Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
December 2020
-
Media ReleaseNovartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care)1 Detailed…
-
Media ReleaseNovartis receives EU approval for Leqvio®* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year**Leqvio® (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe1-3 Cardiovascular disease causes 3.9…
-
Media ReleaseNovartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancerFindings presented at SABCS from largest intrinsic subtype analysis show Kisqali is unique among CDK4/6 inhibitors, delivers consistent efficacy across main HR+/HER2- intrinsic subtypes1Benefit seen…
-
Media ReleaseNovartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancerMONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1Kisqali plus endocrine therapy had a median OS of nearly five years (58.7…
-
Media ReleaseNovartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trialAt 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase…
-
Media ReleaseNovartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomasInterim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1…
-
Media ReleaseNovartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHDResults of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms1Chronic graft-versus-host disease (GvHD) is a life-threatening…
-
Featured NewsThe Co-Creating Impact Summit for the society and the planet
The Co-Creating Impact Summit happening on December 9th, 2020, will gather experts inside and outside of Novartis to continue our work of improving our impact on the society and the planet.
-
Featured NewsWhy healthcare’s digital moment is now
Novartis Chief Digital Officer, Bertrand Bodson, and Microsoft Corporate Vice President Research & Incubation, Peter Lee, discussed why healthcare’s digital moment is now.
-
In The NewsMoving towards the next normalHow changes driven by COVID-19 may shape pharma manufacturing in the long term.
November 2020
Pagination
- ‹ Previous page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- …
- 152
- › Next page